First patient receives dengue vaccine in phase 3 trial : healio

referring to healio

First patient receives dengue vaccine in phase 3 trial

First patient receives dengue vaccine in phase 3 trial

Takeda Pharmaceutical has initiated its phase 3 Tetravalent Immunization against Dengue Efficacy Study and vaccinated its first patient with TAK-003, a live-attenuated tetravalent dengue vaccine candidate, according to a press release.In the TIDES trial, approximately 20,000 healthy children aged 4 to 16 years living in dengue-endemic countries in Latin America and Asia will be dosed with TAK-003 — a vaccine based on a live-attenuated dengue serotype 2 virus.The double blind, randomized and placebo-controlled trial will evaluate the efficacy of the vaccine in protecting patients against symptomatic dengue fever caused by any of the four virus serotypes, regardless of age and whether the individual has previously been exposed to the virus, the release said.


moreover from foxnews

Private health-care institutions get dengue vaccine in Mexico

Private health-care institutions get dengue vaccine in Mexico

Sanofi Pasteur, a unit of French pharmaceutical giant Sanofi, said it was launching the first vaccine developed to fight dengue in Mexico, but the medicine would only be made available to private health-care institutions for now.The vaccine is designed to help reduce outbreaks of the disease and assist doctors in treating people infected with the virus, Sanofi Pasteur said in a statement.Dengue, a serious viral disease transmitted by the Aedes aegypti mosquito, is characterized by high fever, intense headaches, muscle pain, gastro-intestinal problems and rashes.


in like manner gmanetwork

Mexico joins Philippines, Brazil with dengue vaccine

Mexico joins Philippines, Brazil with dengue vaccine